Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

4P - IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cells

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Alessio Ugolini

Citation

Annals of Oncology (2020) 31 (suppl_7): S1417-S1424. 10.1016/annonc/annonc389

Authors

A. Ugolini1, I. Zizzari2, F. Ceccarelli3, A. Botticelli3, T. Colasanti3

Author affiliations

  • 1 Experimental Medicine, Sapienza - Università di Roma, 00161 - Rome/IT
  • 2 Sapienza - Università di Roma, Rome/IT
  • 3 Policlinico Umberto I, Rome/IT
More

Abstract 4P

Background

Despite anti-PD-1 targeting with Immune-Checkpoint Inhibitors (ICIs) has markedly improved the survival of Non-Small Cells Lung Cancer (NSCLC) patients, the onset of both primary and secondary resistances still occur in the majority of patients. The association between autoimmunity and cancer is an area of particular interest being the latter, as in the case of autoantibodies, an indication of a dysfunctional immune system.

Methods

We enrolled 42 patients with metastatic NSCLC before and during anti-PD-1 treatment, evaluating circulating levels of different autoantibodies and Peripheral Blood Mononuclear Cells (PBMCs) populations.

Results

The presence of IgM-Rheumatoid Factor (IgM-RF) in patients sera was strongly associated (OR, 7,66; 95% CI, 1.62 to 36.18; p=0.005) with the development of early progression. IgM-RF positivity resulted also as an important prognostic factor for a worse outcome in terms of both PFS (p=0.035) and OS (p=0.034), with a more marked reduction of PFS rate (p=0.002) identified when patients were further stratified based on IgM-RF titers. IgM-RF+ patients showed a significant reduction (p=0.02) of the circulating tumor-specific CD137+ T-cell population. To confirm the importance of this T-cell population in driving patients response, an higher percentage of CD137+ T-cells at baseline correlated with a better outcome in terms of both PFS (p=0.006) and OS (p=0.002). Mechanistic experiments demonstrate that IgM-RF preferentially bound to naïve and central memory T-cells (p<0.0001) and a robust impairment (p=0.0001) of their migratory ability in response to CCL-19 was observed when exposed to IgM-R.

Conclusions

IgM-RF can be ascribed as a novel biomarker that is able to predict the development of early progression and, in addition, as a prognostic factor for a reduced PFS and OS in NSCLC patients in treatment with anti-PD-1 ICIs. The reduction of anti-tumor CD137+ T-cells that was observed in IgM-RF+ patients could make account for the reduced survival of the patients, since the frequency of this population in the blood of NSCLC patients resulted as an independent prognostic factor for a better outcome.

Legal entity responsible for the study

The authors.

Funding

Università Sapienza di Roma.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.